Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.

Next Previous
X
Search
Trial Profile

Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Veliparib (Primary)
  • Indications Carcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Seminoma; Teratoma; Testicular cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2021 Status changed to discontinued as 8 patients were alive and progression-free at 12 months among the first 15 patients hence the study was terminated and this study failed to achieve its primary endpoint
    • 29 May 2021 Primary endpoint 12-month PFS (Percentage of patients that will be free of disease progression according to RECIST criteria 12-months after the first administration of the treatment.)has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top